Complement C5 Contributes to Brain Injury After Subarachnoid Hemorrhage

• Published in: Translational stroke research 2020-08, Vol.11 (4), p.678-688
• Main Authors: van Dijk, Bart J., Meijers, Joost C.M., Kloek, Anne T., Knaup, Veronique L., Rinkel, Gabriel J.E., Morgan, B. Paul, van der Kamp, Marije J., Osuka, Koji, Aronica, Eleonora, Ruigrok, Ynte M., van de Beek, Diederik, Brouwer, Matthijs, Pekna, Marcela, Hol, Elly M., Vergouwen, Mervyn D.I.
• Format: Article
• Language: English
• Subjects: Adult; Age; Aged; Aneurysms; Animals; Autopsies; Biomedical and Life Sciences; Biomedicine; Brain - metabolism; Brain - pathology; Brain Injuries - complications; Brain Injuries - genetics; Brain Injuries - metabolism; Cardiology; Complement C5 - genetics; Complement C5 - metabolism; Disease Models, Animal; Fatalities; Female; Females; Genetic Predisposition to Disease; Genomes; Genotype; Hemorrhage; Humans; Ischemia; Male; Males; Medical imaging; Middle Aged; Neurology; Neurosciences; Neurosurgery; Neurovetenskaper; Original; Original Article; Patients; Plasma; Polymorphism, Single Nucleotide; Subarachnoid Hemorrhage - complications; Subarachnoid Hemorrhage - genetics; Subarachnoid Hemorrhage - metabolism; Traumatic brain injury; Vascular Surgery
• ISSN: 1868-4483; 1868-601X; 1868-601X
• DOI: 10.1007/s12975-019-00757-0

Previous studies showed that complement activation is associated with poor functional outcome after aneurysmal subarachnoid hemorrhage (SAH). We investigated whether complement activation is underlying brain injury after aneurysmal SAH ( n  = 7) and if it is an appropriate treatment target. We investigated complement expression in brain tissue of aneurysmal SAH patients ( n  = 930) and studied the role of common genetic variants in C3 and C5 genes in outcome. We analyzed plasma levels ( n  = 229) to identify the functionality of a single nucleotide polymorphism (SNP) associated with outcome. The time course of C5a levels was measured in plasma ( n  = 31) and CSF ( n  = 10). In an SAH mouse model, we studied the extent of microglia activation and cell death in wild-type mice, mice lacking the C5a receptor, and in mice treated with C5-specific antibodies ( n  = 15 per group). Brain sections from aneurysmal SAH patients showed increased presence of complement components C1q and C3/C3b/iC3B compared to controls. The complement component 5 ( C5 ) SNP correlated with C5a plasma levels and poor disease outcome. Serial measurements in CSF revealed that C5a was > 1400-fold increased 1 day after aneurysmal SAH and then gradually decreased. C5a in plasma was 2-fold increased at days 3–10 after aneurysmal SAH. In the SAH mouse model, we observed a ≈ 40% reduction in both microglia activation and cell death in mice lacking the C5a receptor, and in mice treated with C5-specific antibodies. These data show that C5 contributes to brain injury after experimental SAH, and support further study of C5-specific antibodies as novel treatment option to reduce brain injury and improve prognosis after aneurysmal SAH.